Pediatric blood & cancer · 2026
Augmented Reality-Supported Cognitive Behavioral Therapy for Children With Cancer: A Multicenter, Three-Arm Randomized Controlled Trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mutluer Tuba, Özcan Morey Aslıhan, Karaturhan Pelin, Aslan Genç Herdem, Markaroğlu Elvan Romina, Erbey Fatih, Eker Nurşah, Küpesiz Alphan, Tayfun Küpesiz Funda, Güler Elif, Yantaç Asım Evren, Kuşcu Mehmet Kemal, Kebudi Rejin
Аннотация
BACKGROUND: Children undergoing cancer treatment experience high anxiety, procedural distress, and impaired quality of life (QoL), yet scalable psychosocial interventions remain scarce. We tested whether an augmented reality (AR)-supported, manualized cognitive behavioral therapy program (AR-CBT; the "My Hospital Buddy Ida" application plus a workbook) improves psychosocial outcomes more than standard CBT or usual care.
PROCEDURE: In a multicenter, three-arm, assessor-blinded randomized controlled trial at six recruiting sites in Türkiye, 114 children aged 6-12 years within the first 4 months of chemotherapy were randomized to AR-CBT, standard CBT (workbook only), or usual care; both active arms received nine clinician-delivered sessions. The primary outcome was the child-reported Pediatric Quality of Life Inventory (PedsQL) Cancer Module total score. Pre-specified secondary outcomes included resilience, parent-reported behavior problems, state anxiety, parent-proxy QoL, and anticipatory fatigue, nausea, and distress. Analyses adjusted for baseline and age.
RESULTS: Ninety-three children completed the trial (AR-CBT n = 36; standard CBT n = 28; usual care n = 29). AR-CBT yielded higher post-treatment PedsQL total scores than both comparators (F[2,88] = 12.98, p < 0.001, partial η2 = 0.23), with parallel gains across most subscales. Resilience was higher after AR-CBT (p < 0.001), parent-reported anxiety problems decreased (F = 5.75, p = 0.004), and anticipatory fatigue, nausea, and distress all declined (p ≤ 0.014). Acceptability was high in all arms (97.2% in AR-CBT; between-arm differences nonsignificant).
CONCLUSIONS: AR-supported CBT was feasible, acceptable, and superior to standard CBT and usual care for QoL, resilience, and symptom-related distress, supporting AR-CBT as a scalable vehicle for evidence-based psychotherapy in pediatric oncology.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT07742059 (first submitted July 21, 2026, first posted August 3, 2026). Enrollment began in April 2024, so registration was retrospective. The study design and primary outcome were pre-specified in the Institutional Review Board (IRB)-approved protocol (2023.128.IRB1.040, approved April 12, 2023) before enrollment began.
PROCEDURE: In a multicenter, three-arm, assessor-blinded randomized controlled trial at six recruiting sites in Türkiye, 114 children aged 6-12 years within the first 4 months of chemotherapy were randomized to AR-CBT, standard CBT (workbook only), or usual care; both active arms received nine clinician-delivered sessions. The primary outcome was the child-reported Pediatric Quality of Life Inventory (PedsQL) Cancer Module total score. Pre-specified secondary outcomes included resilience, parent-reported behavior problems, state anxiety, parent-proxy QoL, and anticipatory fatigue, nausea, and distress. Analyses adjusted for baseline and age.
RESULTS: Ninety-three children completed the trial (AR-CBT n = 36; standard CBT n = 28; usual care n = 29). AR-CBT yielded higher post-treatment PedsQL total scores than both comparators (F[2,88] = 12.98, p < 0.001, partial η2 = 0.23), with parallel gains across most subscales. Resilience was higher after AR-CBT (p < 0.001), parent-reported anxiety problems decreased (F = 5.75, p = 0.004), and anticipatory fatigue, nausea, and distress all declined (p ≤ 0.014). Acceptability was high in all arms (97.2% in AR-CBT; between-arm differences nonsignificant).
CONCLUSIONS: AR-supported CBT was feasible, acceptable, and superior to standard CBT and usual care for QoL, resilience, and symptom-related distress, supporting AR-CBT as a scalable vehicle for evidence-based psychotherapy in pediatric oncology.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT07742059 (first submitted July 21, 2026, first posted August 3, 2026). Enrollment began in April 2024, so registration was retrospective. The study design and primary outcome were pre-specified in the Institutional Review Board (IRB)-approved protocol (2023.128.IRB1.040, approved April 12, 2023) before enrollment began.